Comparison of the efficacy and safety of hydroxychloroquine versus teneligliptin as add on therapy in uncontrolled type 2 diabetes mellitus: a randomized, prospective and open labelled study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20260427Keywords:
Type 2 diabetes mellitus, Hydroxychloroquine, TeneligliptinAbstract
Background: Type 2 Diabetes Mellitus (T2DM) is a multifactorial metabolic disorder characterized by chronic hyperglycaemia resulting from insulin resistance and β-cell dysfunction. Despite combination therapy with metformin and sulfonylureas, many patients fail to achieve optimal glycemic control, necessitating additional agents. Hydroxychloroquine (HCQS), an immunomodulatory drug, has shown potential antidiabetic and anti-inflammatory effects, while teneligliptin, a DPP-4 inhibitor, improves insulin secretion through incretin modulation.
Methods: A randomized, prospective, open-label study was conducted over three months in 100 T2DM patients aged 18–60 years with HbA1c ≥7.5%. Participants received either HCQS 400 mg once daily or teneligliptin 20 mg once daily, in addition to metformin and glimepiride. Fasting blood glucose (FBG), postprandial blood glucose (PPBG), and HbA1c were assessed at baseline, day 28, 56, and 84. Data were analyzed using ANOVA and unpaired t-tests, with p<0.05 considered significant.
Results: Both HCQS and teneligliptin significantly (p<0.001) reduced FBG, PPBG, and HbA1c levels from baseline. Comparative analysis showed a greater reduction in HbA1c with HCQS (p<0.05). No significant differences were observed in BMI or incidence of adverse effects between groups. Mild gastrointestinal symptoms were the most common adverse events.
Conclusions: Both HCQS and teneligliptin were effective and well-tolerated as add-on therapies in uncontrolled T2DM. HCQS demonstrated superior glycemic improvement, suggesting it as an economical and effective adjunct for better glycemic control in Indian patients.
Metrics
References
Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016;12(6):357-70. DOI: https://doi.org/10.1038/nrendo.2016.53
Cheng AY, Leiter LA. Diabetes and cardiovascular disease: the role of glycemic control. Curr diab rep. 2009;9(1):65-72. DOI: https://doi.org/10.1007/s11892-009-0012-y
Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J clin nutr. 2017;71(7):816-24. DOI: https://doi.org/10.1038/ejcn.2017.40
Das AK, Kalra S, Tiwaskar M, Bajaj S, Seshadri K, Chowdhury S, et al. Expert group consensus opinion: role of anti-inflammatory agents in the management of type-2 diabetes (T2D). J Assoc Physicians India. 2019;67(12):65-74.
Kumar A, Prakash AS. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy. JAFES. 2019;34(1):87. DOI: https://doi.org/10.15605/jafes.034.01.13
Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141-7. DOI: https://doi.org/10.2337/diacare.27.1.141
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333-47. DOI: https://doi.org/10.1111/dom.12610
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42. DOI: https://doi.org/10.1007/s00125-014-3460-0
Barnett A. DPP‐4 inhibitors and their potential role in the management of type 2 diabetes. Int J clin pract. 2006;60(11):1454-70. DOI: https://doi.org/10.1111/j.1742-1241.2006.01178.x
Agarwal P, Jindal C, Sapakal V. Efficacy and safety of teneligliptin in Indian patients with inadequately controlled type 2 diabetes mellitus: A randomized, double-blind study. Indian J endocrinol metab. 2018 ;22(1):41-6. DOI: https://doi.org/10.4103/ijem.IJEM_97_16
Jude EB, Trescoli C, Emral R, Ali A, Lubwama R, Palmer K, et al. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study. Diabetes Obes Metab. 2021;23(4):929-37. DOI: https://doi.org/10.1111/dom.14298
Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. The unique pharmacological and pharmacokinetic profile of teneligliptin: implications for clinical practice. Drugs. 2019;79(7):733-50. DOI: https://doi.org/10.1007/s40265-019-01086-0
Pareek A, Chandurkar N, Thomas N, Viswanathan V Deshpande A, Gupta OP, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: A double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30(7):1257-66. DOI: https://doi.org/10.1185/03007995.2014.909393
Singh UP, Baidya B, Singla M, Jain S, Kumar S, Sarogi RK, et al. Efficacy and safety of substituting teneligliptin with hydroxychloroquine in inadequately controlled type 2 diabetes subjects with combination therapy of teneligliptin, metformin and glimepiride with or without other antidiabetic therapy: The TENE-HYQ SHIFT Study. Clinical Diabetology. 2018;7(5):209-14. DOI: https://doi.org/10.5603/DK.2018.0025
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J mol sci. 2020;21(17):6275. DOI: https://doi.org/10.3390/ijms21176275
Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J diabetes res. 2020;2020:5214751. DOI: https://doi.org/10.1155/2020/5214751
Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011;15(4):298-308. DOI: https://doi.org/10.4103/2230-8210.85583
Ramakrishnan S, Ramakrishnan A, Warrier R, Gopal S. Hydroxychloroquine (HCQS) for glycaemic control: a remarkable turnaround in a patient with Type 2 DM. J Endocrinol Sci. 2020;2(1):1-3. DOI: https://doi.org/10.29245/2767-5157/2020/1.1104
Downloads
Published
How to Cite
Issue
Section
